JMP Securities Downgrades Intra-Cellular Therapies (ITCI) to Market Perform
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 19 | New: 38
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 19 | New: 38
Join SI Premium – FREE
JMP Securities downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Market Outperform to Market Perform and removed its price target (prior $55.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $42.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berenberg Downgrades Siemens Healthineers (SHL:GR) (SEMHF) to Hold
- HSBC Downgrades Kunlun Energy Co Ltd. (135:HK) (KUNUF) to Hold
- Mizuho Downgrades Tractor Supply Company (TSCO) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
The Children's Investment Fund (TCI), JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
